CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <\/p>\n
Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that Michael J. Pellini, M.D., president and chief executive officer, will present an overview of the company at the Worldwide Innovative Networking (WIN) 2012 Symposium being held June 28-29 in Paris, France. The WIN Consortium in personalized cancer medicine is initiating a clinical trial that uses FoundationOne, a genomic profile for cancer developed by Foundation Medicine. Details of the trial will be highlighted at the Symposium. <\/p>\n
FoundationOne will allow physicians participating in this trial to test for alterations in clinically-relevant genes known to be associated with human cancer and match these alterations with appropriate targeted therapies or clinical trials, said Dr. John Mendelsohn, chairman of WIN Consortium. WIN and Foundation Medicine are both dedicated to enabling the best treatment possible with the therapies most likely to be effective against an individual patients cancer. We believe this trial is an important step in that direction. <\/p>\n
About WIN Consortium and WIN 2012 Symposium <\/p>\n
WIN Consortium is a network of 22 academic institutions and industries across the globe, initiated by the Cancer Institute Gustave Roussy (IGR), France and University of Texas MD Anderson Cancer Center, USA (MDACC) and focused on international biomarker-driven therapeutic clinical trials. Foundation Medicine joined the consortium in March 2012. <\/p>\n
The WIN 2012 Symposium is dedicated to the efficacy of personalized cancer therapeutics through an open exchange format with investigators from academic institutions and the biopharma industry. <\/p>\n
Foundation Medicine and the clinical trial will be discussed on June 28th during Session 2 of the WIN 2012 Symposium at the Palais des Congrs in Porte Maillot, Paris, France: <\/p>\n
Date & Time: <\/p>\n
Title: <\/p>\n
Presenter: <\/p>\n<\/p>\n
Read the original here: <\/p>\n
WIN Consortium to Conduct a Clinical Trial Using FoundationOne\u2122, Foundation Medicine\u2019s Comprehensive Genomic Profile ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that Michael J. Pellini, M.D., president and chief executive officer, will present an overview of the company at the Worldwide Innovative Networking (WIN) 2012 Symposium being held June 28-29 in Paris, France. Continue reading